Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional ...

Samsung Bioepis and Organon shared that the Food and Drug Administration has designated the Hadlima (adalimumab-bwwd) high- ...

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations ...

Risks and uncertainties include, but are not limited to, expanded brand and class competition in the markets in which Organon operates; trade protection measures and import or export licensing ...

Organon operates primarily in the U.S. Specialty Pharmaceuticals industry, focusing on women’s health products, biosimilars, and established brands. The company has maintained an "Overweight ...

Now, Organon — Merck’s spin-off business that focuses on women ... on one of the world’s most popular social media platforms made sense for the Nexplanon brand, she says, since women aged 18 to 44 are ...

Our investigation concerns whether Organon has violated the federal securities ... in Biosimilars and an 11% y/y drop in Established Brands on the loss of Atozet exclusivity.

That Organon's revenues are shrinking isn't too surprising - the "Established Brands" division Organon inherited from Merck is its biggest contributor to revenues - $887 million in Q1 2025 ...